A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Phase 2 Unknown 70 enrolled Xin-Hua Xu

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy based of cisplatin with sintilimab as first-line therapy for patients with advanced oral cavity squamous cell carcinoma.

Timeline

Start: 2023-01-18
Primary completion: 2025-01-18
Completion: 2025-01-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sintilimab	Monoclonal antibody	—	—

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications